CSR Limited
9 Help Street Chatswood
NSW 2067 Australia
T +612 9235 8000
F +612 9235 8055
E-mail investorrelations@csr.com.au
www.csr.com.au
ABN 90 000 001 276

CSR sale of industrial land at Erskine Park in Western Sydney

CSR Limited today announced that it has entered into a conditional agreement to sell 38 hectares of industrial land at its Erskine Park site in Western Sydney to The GPT Group for $95 million. The transaction is subject to CSR obtaining development approval for third stage industrial development of the former quarry site and requires CSR to complete specified civil works.

CSR Managing Director Alec Brennan, said, "We have accelerated development on the Erskine Park site to meet the rapidly growing demand for industrial land in Western Sydney."

"This sale to The GPT Group is a good deal for our shareholders. It provides excellent returns for the land taking into account associated delivery risk."

Following major transactions to BlueScope Steel, Australand Property Group and now The GPT Group, CSR has secured transactions for around 80 hectares of the 100 hectare site.

CSR will continue to work with local and state development authorities to generate further value for the remaining 20 hectares of land capable of development at Erskine Park, subject to regulatory approvals.

"The Erskine Park development is a good example of CSR Group Property's focus. We maximise returns from the sale of industrial sites at the end of their productive life by advancing the sites through various stages of the development cycle. For the Erskine Park development, this involves obtaining site rezoning and regulatory approvals, as well as managing land rehabilitation and construction of supporting infrastructure," said Mr Alec Brennan

25 October 2005

Media/analyst enquiries:
Stephen Zadro, CSR Investor Relations
Tel: +612 9235 8053 / Mob: 0419 476 504
Email: SZadro@csr.com.au
www.csr.com.au

CSR

BRAINZ

www.brainz.com
ARBN 116 829 675

BrainZ Appendix 4E Filing for year to 31 August 2006 and notification of change in balance date

25 October 2006

Today BrainZ Instruments Limited (BrainZ) has submitted its Appendix 4E Preliminary final report for the year ended 31 August 2006.

The results presented are consistent with the Company's expectations set out in the prospectus of November 2005.

As a result of the parent company Tru-Test Limited applying to the relevant authorities to change its balance date to 31 March, BrainZ also intends to change its balance date to 31 March with effect from 31 March 2007.

Enquiries:

Dr Justin Vaughan
Chief Executive Officer
BrainZ
+64 9 978 8888

Kamini Rambausek
Monsoon Communications
0423 383 335

About BrainZ Instruments Limited:
BrainZ (ASX: BZI) is a New Zealand based medical technology company specializing in the research, development, manufacturing and sale of bedside brain monitoring technology. The BRM2 Brain Monitor, BrainZ's first product, is a unique bedside tool that assists in the detection of brain injury and seizure activity in neonates. It has been specifically designed to assist intensive care staff with clinical decision-making in conjunction with other clinical data and in the direction of care on a day-to-day basis.

The BRM2 monitor has received regulatory approval and is in use in 16 countries worldwide. BrainZ dominates the local Australian and New Zealand markets via direct sales channels. BRM2 monitors are also installed in over 40 leading US hospitals. BrainZ has secured an exclusive agreement with GE Healthcare, a leading supplier of patient monitoring systems, for the distribution of BRM2 Brain Monitors in the USA and UK markets.

BrainZ Instruments was established in 2001 to commercialize pioneering neonatal brain research from the Auckland University's Liggins Institute. BrainZ was acquired by Tru-Test Ltd in September 2002. Tru-Test is a multinational company specialising in electronic technology solutions. BrainZ publicly listed on the Australian Stock Exchange (ASX) in December 2005, raising AU$13 million.